search
Back to results

Closed-loop in Adults With T2D Not Requiring Dialysis (AP-Renal)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
CamAPS HX Closed-loop
Multiple Daily Insulin Injections (Control)
Sponsored by
University of Cambridge
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring diabetes, type 2 diabetes, closed-loop, artificial pancreas, insulin pump therapy, continuous glucose monitoring

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 years or over
  2. Diagnosis of type 2 diabetes using standard diagnostic practice
  3. Current treatment with subcutaneous insulin
  4. Screening HbA1c ≤ 11% (97mmol/mol) on analysis from local laboratory
  5. Subject is willing to perform regular finger-prick blood glucose monitoring
  6. Willingness to wear study devices
  7. Literate in English

Exclusion Criteria:

  1. Physical or psychological condition likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  2. Known or suspected allergy to insulin
  3. Lack of reliable telephone facility for contact
  4. Pregnancy, planned pregnancy, or breast feeding
  5. Severe visual impairment
  6. Severe hearing impairment
  7. Medically documented allergy towards the adhesive (glue) of plasters
  8. Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor
  9. Illicit drugs abuse
  10. Prescription drugs abuse
  11. Alcohol abuse

Sites / Locations

  • Cambridge University Hospitals NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Closed loop insulin delivery

Standard therapy

Arm Description

Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 8 weeks The CamAPS HX closed-loop system comprises: Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data

Participants in the control arm will continue to follow their current diabetes management plan for the 8 week study period. Participants will be wear a masked continuous glucose monitoring (CGM) system during the 8 week study period

Outcomes

Primary Outcome Measures

Time in the target glucose range (3.9 to 10.0 mmol/l)
Percentage of time spent with sensor glucose readings in the target range from 3.9 to 10.0mmol/l

Secondary Outcome Measures

Time spent above target glucose (10.0 mmol/l)
Percentage of time spent with sensor glucose readings above target glucose (10.0 mmol/l)
Mean glucose
Mean sensor glucose level
Time spent in hypoglycaemia (<3.9 mmol/l)
Percentage of time spent with sensor glucose readings <3.9 mmol/L
Standard deviation of glucose levels
Standard deviation of glucose levels
Coefficient of variation of glucose levels
Coefficient of variation of glucose levels
Time spent below <3.0 mmol/l
Percentage of time spent with sensor glucose readings <3.0 mmol/l
Time in hyperglycaemia > 16.7 mmol/l
Percentage of time with glucose levels in hyperglycaemia > 16.7 mmol/l
Time in significant hyperglycaemia (> 20 mmol/l)
Percentage of time with glucose levels in significant hyperglycaemia (> 20 mmol/l)
Glycated haemoglobin (HbA1c)
HbA1c measured at the end of each study period
Total insulin dose
Average daily total insulin requirements

Full Information

First Posted
January 6, 2021
Last Updated
May 25, 2022
Sponsor
University of Cambridge
search

1. Study Identification

Unique Protocol Identification Number
NCT04701424
Brief Title
Closed-loop in Adults With T2D Not Requiring Dialysis
Acronym
AP-Renal
Official Title
An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy, Safety and Utility of Fully Closed-loop Insulin Delivery in Comparison With Standard Care in Adults With Type 2 Diabetes Not Requiring Dialysis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
December 16, 2020 (Actual)
Primary Completion Date
March 30, 2022 (Actual)
Study Completion Date
March 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Cambridge

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main objective of this study is to determine the efficacy, safety and utility of fully automated closed-loop glucose control in the home setting over an 8 week period in adults with type 2 diabetes (T2D). This study builds on previous and on-going studies of closed-loop systems that have been performed in Cambridge in adults with type 1 diabetes in the home setting, and in adults with type 2 diabetes in the inpatient setting. This is an open-label, single centre, randomised, cross-over study, involving two home study periods during which glucose levels will be controlled either by a fully automated closed-loop system or by participants' usual insulin therapy in random order. Each treatment arm is 8 weeks long with a 2-4 week washout period between treatments. A total of up to 30 participants with T2D will be recruited through outpatient clinics to allow for 24 completed participants available for assessment. Participants will receive appropriate training by the research team on the safe use of the study devices (insulin pump and continuous glucose monitoring (CGM) and closed-loop insulin delivery system). Participants in the control arm will continue with standard therapy and will wear a blinded CGM system. The primary outcome is time spent with glucose levels in the target range between 3.9 and 10.0 mmol/L as recorded by CGM. Secondary outcomes are the time spent with glucose levels above and below target, as recorded by CGM, and other CGM-based metrics in addition to insulin requirements. Safety evaluation comprises the tabulation of severe hypoglycaemic episodes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
diabetes, type 2 diabetes, closed-loop, artificial pancreas, insulin pump therapy, continuous glucose monitoring

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Closed loop insulin delivery
Arm Type
Experimental
Arm Description
Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 8 weeks The CamAPS HX closed-loop system comprises: Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data
Arm Title
Standard therapy
Arm Type
Active Comparator
Arm Description
Participants in the control arm will continue to follow their current diabetes management plan for the 8 week study period. Participants will be wear a masked continuous glucose monitoring (CGM) system during the 8 week study period
Intervention Type
Device
Intervention Name(s)
CamAPS HX Closed-loop
Intervention Description
The CamAPS HX closed-loop system comprises: Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data.
Intervention Type
Other
Intervention Name(s)
Multiple Daily Insulin Injections (Control)
Intervention Description
Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
Primary Outcome Measure Information:
Title
Time in the target glucose range (3.9 to 10.0 mmol/l)
Description
Percentage of time spent with sensor glucose readings in the target range from 3.9 to 10.0mmol/l
Time Frame
8 week intervention period
Secondary Outcome Measure Information:
Title
Time spent above target glucose (10.0 mmol/l)
Description
Percentage of time spent with sensor glucose readings above target glucose (10.0 mmol/l)
Time Frame
8 week intervention period, both arms
Title
Mean glucose
Description
Mean sensor glucose level
Time Frame
8 week intervention period, both arms
Title
Time spent in hypoglycaemia (<3.9 mmol/l)
Description
Percentage of time spent with sensor glucose readings <3.9 mmol/L
Time Frame
8 week intervention period, both arms
Title
Standard deviation of glucose levels
Description
Standard deviation of glucose levels
Time Frame
8 week intervention period, both arms
Title
Coefficient of variation of glucose levels
Description
Coefficient of variation of glucose levels
Time Frame
8 week intervention period, both arms
Title
Time spent below <3.0 mmol/l
Description
Percentage of time spent with sensor glucose readings <3.0 mmol/l
Time Frame
8 week intervention period, both arms
Title
Time in hyperglycaemia > 16.7 mmol/l
Description
Percentage of time with glucose levels in hyperglycaemia > 16.7 mmol/l
Time Frame
8 week intervention period, both arms
Title
Time in significant hyperglycaemia (> 20 mmol/l)
Description
Percentage of time with glucose levels in significant hyperglycaemia (> 20 mmol/l)
Time Frame
8 week intervention period, both arms
Title
Glycated haemoglobin (HbA1c)
Description
HbA1c measured at the end of each study period
Time Frame
8 week intervention period, both arms
Title
Total insulin dose
Description
Average daily total insulin requirements
Time Frame
8 week intervention period, both arms
Other Pre-specified Outcome Measures:
Title
Number of episodes of severe hypoglycaemia
Description
Safety evaluation
Time Frame
8 week intervention period, both arms
Title
Number of subjects experiencing severe hypoglycaemia
Description
Safety evaluation
Time Frame
8 week intervention period, both arms
Title
Frequency and nature of other adverse events or serious adverse events
Description
Safety evaluation
Time Frame
8 week intervention period, both arms
Title
Percentage of time of closed-loop operation
Description
Utility evaluation
Time Frame
8 week intervention period, both arms
Title
Percentage of time of CGM availability
Description
Utility evaluation
Time Frame
8 week intervention period, both arms

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or over Diagnosis of type 2 diabetes using standard diagnostic practice Current treatment with subcutaneous insulin Screening HbA1c ≤ 11% (97mmol/mol) on analysis from local laboratory Subject is willing to perform regular finger-prick blood glucose monitoring Willingness to wear study devices Literate in English Exclusion Criteria: Physical or psychological condition likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator Known or suspected allergy to insulin Lack of reliable telephone facility for contact Pregnancy, planned pregnancy, or breast feeding Severe visual impairment Severe hearing impairment Medically documented allergy towards the adhesive (glue) of plasters Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor Illicit drugs abuse Prescription drugs abuse Alcohol abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roman Hovorka, PhD
Organizational Affiliation
University of Cambridge
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cambridge University Hospitals NHS Foundation Trust
City
Cambridge
State/Province
Cambridgeshire
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Fully anonymised data may be shared with third parties (EU or non-EU based) for the purposes of advancing management and treatment of diabetes.

Learn more about this trial

Closed-loop in Adults With T2D Not Requiring Dialysis

We'll reach out to this number within 24 hrs